![]() |
Name |
bis-nonactic-homononactic trilactone
|
Molecular Formula | C31H50O9 | |
IUPAC Name* |
5-ethyl-2,11,14,20,23-pentamethyl-4,13,22,28,29,30-hexaoxatetracyclo[23.2.1.17,10.116,19]triacontane-3,12,21-trione
|
|
SMILES |
CCC1CC2CCC(O2)C(C)C(=O)OC(C)CC2CCC(O2)C(C)C(=O)OC(C)CC2CCC(O2)C(C)C(=O)O1
|
|
InChI |
InChI=1S/C31H50O9/c1-7-22-16-25-10-13-27(39-25)20(5)30(33)36-17(2)14-23-8-11-26(37-23)19(4)29(32)35-18(3)15-24-9-12-28(38-24)21(6)31(34)40-22/h17-28H,7-16H2,1-6H3/t17-,18-,19+,20+,21+,22-,23-,24-,25-,26+,27+,28+/m1/s1
|
|
InChIKey |
KAINWDADJCHLRS-XEGQTWRHSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 566.73 | ALogp: | 4.9 |
HBD: | 0 | HBA: | 9 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 106.6 | Aromatic Rings: | 4 |
Heavy Atoms: | 40 | QED Weighted: | 0.309 |
Caco-2 Permeability: | -4.804 | MDCK Permeability: | 0.00010274 |
Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.001 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.611 |
Blood-Brain-Barrier Penetration (BBB): | 0.014 | Plasma Protein Binding (PPB): | 77.81% |
Volume Distribution (VD): | 1.624 | Fu: | 4.36% |
CYP1A2-inhibitor: | 0.003 | CYP1A2-substrate: | 0.1 |
CYP2C19-inhibitor: | 0.011 | CYP2C19-substrate: | 0.901 |
CYP2C9-inhibitor: | 0.002 | CYP2C9-substrate: | 0.071 |
CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.165 |
CYP3A4-inhibitor: | 0.524 | CYP3A4-substrate: | 0.728 |
Clearance (CL): | 14.8 | Half-life (T1/2): | 0.019 |
hERG Blockers: | 0.015 | Human Hepatotoxicity (H-HT): | 0.957 |
Drug-inuced Liver Injury (DILI): | 0.871 | AMES Toxicity: | 0.015 |
Rat Oral Acute Toxicity: | 0.461 | Maximum Recommended Daily Dose: | 0.89 |
Skin Sensitization: | 0.906 | Carcinogencity: | 0.317 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.036 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004445 | ![]() |
0.740 | D0KK2E | ![]() |
0.275 | ||
ENC002054 | ![]() |
0.450 | D09WCM | ![]() |
0.265 | ||
ENC004935 | ![]() |
0.270 | D0Z4UN | ![]() |
0.246 | ||
ENC004418 | ![]() |
0.263 | D02YIZ | ![]() |
0.239 | ||
ENC003461 | ![]() |
0.226 | D04JMQ | ![]() |
0.236 | ||
ENC001476 | ![]() |
0.217 | D03LJR | ![]() |
0.236 | ||
ENC003248 | ![]() |
0.206 | D0Z1ZM | ![]() |
0.235 | ||
ENC001946 | ![]() |
0.204 | D06OMK | ![]() |
0.231 | ||
ENC004466 | ![]() |
0.204 | D09YHJ | ![]() |
0.230 | ||
ENC003808 | ![]() |
0.203 | D0V3GA | ![]() |
0.227 |